Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Attenuat CLA is a nutraceutical product developed and marketed by Laboratorios Lafedar, an Argentine pharmaceutical company. The active ingredient is conjugated linoleic acid (CLA), a naturally occurring fatty acid provided in 1000 mg capsules. It is marketed as a dietary supplement with weight loss (adelgazante) and energizing (energizante) properties. CLA is believed to influence body composition by modulating lipid metabolism, specifically by inhibiting fat storage in adipose tissue and promoting fatty acid oxidation in muscle. In the Argentine market, Attenuat CLA is classified and approved as a nutraceutical/dietary supplement rather than a prescription pharmaceutical medication.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Attenuat CLA.